Dexamethasone May Not Improve Outcomes in Chronic Subdural Hematoma
Treatment of symptomatic chronic subdural hematoma with dexamethasone may worsen outcomes compared with placebo.
Bleeding Disorders
BLEEDING DISORDERS
LATEST ARTICLES
Fibrinogen Concentrate for Bleeding Episodes in Pediatric Congenital Fibrinogen Deficiency
Among pediatric patients with congenital fibrinogen deficiency, the administration of human fibrinogen concentrate may be efficacious for on-demand treatment and surgical prophylaxis.
Heparin, von Willebrand Factor Interaction to Predict Bleeding During Cardiopulmonary Bypass
Predicting bleeding during cardiopulmonary bypass is complex and not captured by tests, including measuring von Willebrand factor interaction.
Additional Hemostatic Agents With Emicizumab Safe in Patients With Hemophilia A Undergoing Surgery
Patients with hemophilia A who are treated with emicizumab may safely receive additional hemostatic agents when undergoing surgery.
Mycophenolate, Corticosteroids as First-Line Treatment for Immune Thrombocytopenia
Although mycophenolate is often used as second-line treatment for immune thrombocytopenia, its efficacy as first-line treatment in combination with corticosteroids is unknown.
von Willebrand Factor Multimer Semiautomated Densitometric Analysis Demonstrates High Accuracy
Research presented at the 2020 annual meeting of the American Society of Hematology reveals semiautomatic densitometric analysis of von Willebrand factor multimers to have excellent accuracy in clinical practice.
Use of Empiric Therapeutic Anticoagulation in Critically Ill Patients With COVID-19
Researchers evaluated coagulation-linked complications in critically ill patients with COVID-19 and survival outcomes following therapeutic anticoagulation.
How Does Use of Fibrinogen Concentrate Impact Blood Component Transfusion after Cardiac Surgery?
The use of PCCs may benefit patients who experience bleeding after cardiopulmonary bypass surgery by decreasing RBC and platelet transfusions.
Thromboelastography for Patients With Slow-Flow Vascular Abnormalities
In minor procedures, coagulation differences may not be clinically significant to determine bleeding or thrombotic periprocedure complication risks.
Activated Prothrombin Complex Concentrate for Reversal of Apixaban- and Rivaroxaban-Associated Major Bleeding
A team of investigators provided a real-world understanding of apixaban or rivaroxaban-linked acute bleeding events in patients receiving aPCC.
Survey Results Suggest Patients With Hemophilia Value US Hemophilia Treatment Centers
According to survey results, patients with hemophilia appear to be satisfied with care received at US hemophilia treatment centers.
Hemophilia A: Primary Prophylaxis Linked With Impaired Quality of Life
Researchers compared quality of life and work-related function in patients with hemophilia A with patients with osteoarthritis and the general population.
Assessing the Safety of Epidural Analgesia During Pregnancy in Patients With Type 1 von Willebrand Disease
Epidural analgesia in pregnant women with VWD type 1 appears to be safe with VWF and factor VIII levels of 80% or more in the third trimester.
N8-GP Appears Safe and Efficacious for Prophylaxis, Bleeding Control in Hemophilia A
For patients with severe hemophilia A, N8-GP was safe and efficacious according to the results of the pathfinder clinical programs.
Thromboelastography and Turbidimetry Synergistically Characterize Clot Formation
Study results suggest that TEG and turbidimetry measure clot formation in separate ways and should be used synergistically.
Novel Pharmacokinetics Model of Recombinant von Willebrand Factor in von Willebrand Disease, Severe Hemophilia A
Researchers developed a novel population pharmacokinetics model of recombinant von Willebrand factor in patients with VWD or severe hemophilia A.
PROPEL Study: Patients With Severe Hemophilia A Benefit From Elevated FVIII Troughs
Rurioctocog alfa pegol targeting FVIII troughs benefits patients with severe hemophilia A, according to research presented at the THSNA 2020 virtual meeting.
Reversing Factor Xa Inhibitor–Related Bleeding With 4-Factor-Prothrombin Complex Concentrate
In a comprehensive evaluation, investigators assessed the efficacy and safety of 4F-PCC for oral fXa inhibitor–related emergent bleeding.
Novel Fusion Protein to Sustain Factor VIII Activity in Hemophilia A
BIVV001, a novel fusion protein, has longer half-life than recombinant factor VIII products and may be a safe therapy for hemophilia A.
Low Bone Mass Common in Patients With Hemophilia
Investigators assessed whether there was a link between low bone mineral density, 25(OH)D concentrations, and bone turnover markers in hemophilia.
Label Mix-Up Prompts Recall of IV Amiodarone, Tranexamic Acid
Inadvertent administration may result in serious adverse events.
Effects of ABO Blood Group on von Willebrand Factor Biology, Primary Hemostasis
ABO blood group has been associated with cardiovascular disease and thrombotic risk; however, influences on hemostasis are still not well understood.
Understanding the Association Between COVID-19, Thromboembolism, and Therapeutic Anticoagulation
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Von Willebrand Factor Level Associated With Long-Term Outcomes in Patients After Coronary Stenting
Researchers studied the effect of certain biomarkers on long-term adverse cardiovascular outcomes in patients with coronary morbidities undergoing PCI.
PwHA: Annualized Bleeding Rates High With Current Treatment Standards
There is a need for novel, effective treatments for pediatric patients with hemophilia A with FVIII inhibitors to reduce annualized bleeding rates.
Risk Factors for Early Post-Surgical Wound Complications in Hemophilia
Investigators studied the frequency and risk factors linked to wound healing complications after elective orthopedic surgery in patients with hemophilia.
Prevalence of Endotheliopathy in COVID-19–Associated Coagulopathy
A team of investigators sought to determine whether endotheliopathy is involved in COVID-19–associated coagulopathy pathogenesis.
Assessing Prevalence and Treatment of Cold Agglutinin Disease in Warmer and Colder Climates
Investigators aimed to improve the understanding of the epidemiologic, clinical, and laboratory findings of cold agglutinin disease.
Characterization of NBEAL2 Genetic Variants in Gray Platelet Syndrome
In addition to well-described platelet defects in gray platelet syndrome, immune defects, such as abnormal cells also exist.
Deep Vein Thrombosis Detection in Patients With Hemophilia A Undergoing Total Knee Arthroplasty
A prospective, single-center study aimed to determine the prevalence of DVT after TKA among patients with hemophilia A and found that contrast-enhanced CT led to better detection compared with ultrasound.
Fetal Precautions Can Affect Mode of Delivery in Congenital Bleeding Disorders
In about 10% of pregnancies in which the mother has a congenital bleeding disorder, recommended fetal precautionary measures may influence the mode of delivery.
The Utility of Disease Registries to Assess Inhibitor Development in Hemophilia A
Researchers assessed whether hemophilia A disease registry could be used instead of clinical studies to determine orphan drug safety in pediatric patients.
Importance of Bleeding Phenotype, Diagnostic Trends in Congenital Platelet Defects
There was a median bleeding score of 21 among patients with Glanzmann thrombasthenia, 9 in Bernard-Soulier syndrome, 10 in dense granule deficiency, 7 in ADP pathway defect, 8 in TxA2 pathway defect, 6 in isolated thrombocytopenia, and 8 in complex abnormalities.
Increasing Factor IX Levels May Be Independent of Puberty in Children With Hemophilia B Leyden
Genetic mutations associated with the heterogeneity of hemophilia B Leyden may also be linked to mechanisms that increase factor IX levels with age.
VTE-BLEED Score May Not Accurately Differentiate Patients With VTE for Bleeding Risk
VTE-BLEED prognostic scores did not accurately identify patients with VTE who were at high risk of bleeding events.
von Willebrand Disease: Recent Developments in Diagnosis, Treatments
New developments in lab assays have allowed for more specialized assessments of VWD activity, leading to better diagnoses and various treatment options.
von Willebrand Disease False Levels, Misdiagnosis Still an Issue With Off-Site Testing
The percentage of discordance in onsite and off-site laboratory testing of von Willebrand disease remains high.
Successful Management of Severe COVID-19 in Otherwise Healthy Pediatric Patient
Sustained improvement was noted after the administration of tocilizumab, an interleukin-6 antagonist.
United States Hemophilia Occurrence Rate Higher Than Previously Measured
The exact number of hemophilia cases are unknown and estimates of the size and characteristics of the US hemophilia population are needed for healthcare planning and resource needs assessment.
Genetic Mosaicism and Transmission of Hemophilia
Approximately 30% of patients with hemophilia are considered sporadic cases, causing a challenge when determining carrier status and disease transmission risk to offspring.
Bleeding Risk Assessed With Concomitant Direct Oral Anticoagulants and Verapamil or Diltiazem
Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
Characterizing Healthcare Needs, Utilization in Female Patients With Hemophilia A
Identifying hemophilia A in women and girls with factor VIII deficiency with bleeding events using healthcare claims still remains a challenge.
Patterns of Type 2 von Willebrand Disease in Patients in Iran
Researchers assessed 136 patients with VWD in Iran over 13 years to characterize clinical and molecular patterns associated with the disease.
FDA Approves Sevenfact for Hemophilia A or B With Inhibitors
The FDA has approved Sevenfact (coagulation factor VIIa [recombinant]-jncw; LFB Biotechnologies) for the treatment and control of bleeding episodes occurring in patients aged ≥12 years with hemophilia A or B with inhibitors.
Caution Urged for Genetic Screening in Children Suspected of Having Inherited Bleeding Disorders
The authors stated, however, that genetic screening should be used with caution in children.
Age May Affect Factor VIII Levels in Nonsevere Hemophilia A
Neither factor VIII clotting activity nor factor VIII antigens were significantly different for any blood group in patients with nonsevere hemophilia A.
Exposure to Opioids in Pediatric and Adult Patients With Hemophilia
Researchers found that exposure to opioids in patients with hemophilia may be underreported in the American Thrombosis and Hemostasis Network dataset.
Von Willebrand Factor Plasma Levels and Risk for Major Adverse Cardiovascular Events
Patients who experienced major adverse cardiovascular events reported higher von Willebrand factor plasma levels compared with patients in the control cohort.
Health and Psychological Well-Being in Patients With Hemophilia
Patients with hemophilia were found to experience worse general health but higher levels of psychological well-being compared with individuals in the control arm.
Esperoct Now Available for Treatment of Hemophilia A
Novo Nordisk announced the launch of Esperoct® (antihemophilic factor [recombinant], glycopegylated-exei) for the treatment of adult and pediatric patients with hemophilia A for routine prophylaxis.
Coagulation Disorders and Bleeding Risks With Cefoperazone-Sulbactam
Of patients who received cefoperazone-sulbactam, 9.2% reported a coagulation disorder and 15.7% reported a decrease in platelet count.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Bleeding Disorders
